Whalen Wealth Management Inc. bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 7,685 shares of the biopharmaceutical company’s stock, valued at approximately $602,000.
Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Empowered Funds LLC purchased a new position in shares of Halozyme Therapeutics during the 1st quarter valued at about $755,000. Acadian Asset Management LLC purchased a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $195,000. Hsbc Holdings PLC increased its holdings in Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 5,448 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. raised its stake in Halozyme Therapeutics by 6.2% during the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 650 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
HALO has been the subject of a number of recent analyst reports. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Citizens Jmp raised their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Wells Fargo & Company upped their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Finally, Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $91.20.
Halozyme Therapeutics Trading Up 0.4%
Shares of HALO opened at $108.64 on Tuesday. The firm has a market cap of $12.33 billion, a P/E ratio of 32.43, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $109.10. The company has a 50 day simple moving average of $83.94 and a two-hundred day simple moving average of $73.96.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the previous year, the firm earned $1.54 earnings per share. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares in the company, valued at $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $79,987,320.40. This trade represents a 2.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 64,103 shares of company stock worth $5,226,496 in the last 90 days. 2.50% of the stock is currently owned by corporate insiders.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Featured Articles
- Five stocks we like better than Halozyme Therapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
